1. Introduction {#s0005}
===============

The Lumbee Indian tribe, with 55,000 enrolled members, is the largest Native American tribe in North Carolina. Between 1975 and 1997, Native Americans compared to all other races had the highest relative risk of death from cancer for all cancers except for colorectal cancer in males ([@bb0020]). From 1992 to 2000, even after adjusting for the census tract poverty rate, Native American women had lower five-year survival than did non-Hispanic Whites for all cancers combined ([@bb0095]). During 2000--2009, while all non-Native American racial/ethnic groups experienced at least a 1.1% decline in cancer death rates per year, Native Americans experienced no decline in cancer death rates ([@bb0080]).

Disparities in factors linked to both socioeconomic status and cancer prevention and screening practices have been observed in Native Americans compared to other races in the U.S. Compared to Whites, Native Americans have lower educational status, less access to health care coverage or a source of primary care, and higher poverty rates ([@bb0095]). In a study conducted in Arizona, Native Americans were more likely than Whites to travel greater than 50 miles for endometrial cancer surgery and faced greater barriers to care by a gynecologic oncologist ([@bb0010]). In rural Robeson County, North Carolina, Native American women, as compared to White and Black women, have the lowest levels of education, least insurance coverage, and least accurate knowledge regarding breast carcinoma ([@bb0050]).

However, no direct link between cancer prognosis or survival and culture or SES specific to the Lumbee population has been established. Given the paucity of scientific literature on endometrial cancer in the Lumbee population, we sought to evaluate whether, among patients referred to our institutions, Lumbee heritage is associated with an elevated risk for histologic subtypes of endometrial cancer that carry a worse prognosis.

2. Methods {#s0010}
==========

Following Institutional Review Board approval of retrospectively collected endometrial cancer databases at each institution, we identified Lumbee women with endometrial cancer who were referred for treatment at Duke University Medical Center (Duke) or the University of North Carolina at Chapel Hill Hospitals (UNC) between 1980 and 2014. We developed four Lumbee identification criteria, of which two were required for entry into the Lumbee cohort (cases): (1) Subject has one of the 23 traditional Lumbee last names (Barnes, Bell, Braveboy, Brayboy, Brooks, Bullard, Chavers, Chavis, Cumbo, Cummings, Hammonds, Hunt, Jacobs, Lockileer, Locklear, Lowerie, Lowry, Lowery, Oxendine, Revils, Revels, Strickland, Wilkins); (2) subject is a resident of Robeson County, NC, 38% of whose citizens are members of the Lumbee tribe; (3) subject is identified as Native American/American Indian in medical record; and (4) subject is identified specifically as Lumbee in medical record.

Each Lumbee case was matched to two non-Lumbee controls. Cases and controls were matched by age at diagnosis, institution of diagnosis, body mass index (BMI), and date of surgery. Matched controls were selected randomly if more than one possible control was found. Medical records were reviewed to abstract data on age, BMI, race, ethnicity, insurance status, hypertension, arteriosclerotic cardiovascular disease, diabetes mellitus, smoking history, type of hysterectomy, International Federation of Gynecology and Obstetrics (FIGO) stage based on the 2009 staging system, histology, grade, depth of myometrial invasion, myometrial thickness, tumor size, cervix invasion, fallopian tube and ovarian involvement, performance of lymph node dissection, lymph vascular space invasion (LVSI), pelvic peritoneal cytology, adjuvant therapy received, recurrence, and overall survival (OS). Assessment of ethnicity (Hispanic, non-Hispanic, other) was attempted but information was not available on medical records from Duke University Medical Center.

The Chi-square test was used to compare cases to controls on histologic type (containing serous, clear cell, or carcinosarcoma components vs. none of these components), FIGO grade (grade 3 vs. grades 1--2), and "high-risk cancer", defined as the presence of papillary serous, clear cell, or carcinosarcoma histology or FIGO grade 3. Chi-squared test was also performed to compare cases to controls on clinical and pathological characteristics. Characteristics examined included insurance (private, Medicare, Medicaid, none), hypertension (yes vs. no), cardiovascular diseases, diabetes (yes vs. no), smoking history (yes vs. no), type of hysterectomy (minimally invasive hysterectomy vs. total abdominal hysterectomy), cervix invasion (negative, involvement of glandular epithelium or stromal invasion), number of positive pelvic nodes (0 vs. 1 or more), fallopian tube and ovarian involvement (positive vs. negative), LVSI (positive vs. negative), pelvic peritoneal cytology (positive, negative, atypical), adjuvant chemotherapy (yes vs. no), adjuvant radiation (yes vs. no) and recurrence (yes vs. no). The Kruskal--Wallis test was used to compare central tendencies of continuous variables in the three race cohorts. Variables were considered significant at *p* \< 0.05. Disease-free survival (DFS) was defined as time from date of surgery until first relapse or death of endometrial cancer; for patients still alive without relapse it was censored at the last follow-up visit or death due to other causes. Overall survival (OS) was calculated as time from date of surgery until death of any cause, and was censored at the last follow-up date for those still alive. Survival curves were compared using the log-rank test. Cox proportional hazards multivariate regression models were used to determine if race cohort predicts OS and DFS while adjusting for age and BMI. Statistical analyses were conducted using SAS v. 9.3 software (SAS Institute, Inc., Cary, NC) and survival plots were created using Spotfire S + v. 8.1 (TIBCO, Palo Alto, CA).

3. Results {#s0015}
==========

One hundred eight patients (36 Lumbee, 72 non-Lumbee) were included in this study. Of the 36 Lumbee subjects who met at least two out of the four Lumbee identification criteria, 34 subjects had one of the 23 traditional Lumbee last names; 35 subjects were residents of Robeson County; 34 subjects were identified as Native American/American Indian in medical record; and 3 subjects were identified specifically as Lumbee in medical record.

[Table 1](#t0005){ref-type="table"} describes the pre-operative characteristics of each cohort. The mean age at diagnosis was 61 and the mean BMI was 36. Median year of diagnosis was 2006. There were no significant differences between cohorts in age, BMI, year of surgery, smoking status, cardiovascular disease, diabetes, or hypertension. Among subjects with known insurance status, 4/26 (15%) Lumbee, 15/32 (47%) White and 10/23 (44%) Black subjects had private insurance (*p* = 0.03).

[Table 2a](#t0010){ref-type="table"}, [Table 2b](#t0015){ref-type="table"} describe the operative results and outcomes of each cohort. High-risk cancer (either grade 3 or histological types of serous, clear cell, or carcinosarcoma) was found in 13/35 (37%) Lumbee, 15/49 (31%) White and 12/23 (52%) Black subjects (*p* = 0.2). High-grade (grade 3 vs. grades 1--2) tumors were found in 12/35 (34%) Lumbee, 12/49 (24%) White and 12/23 (52%) Black subjects (*p* = 0.2). Tumors containing high-risk histologic types (serous/clear cell/carcinosarcoma) were found in 10/35 (29%) Lumbee, 9/49 (18%) White, and 10/23 (43%) Black subjects (*p* = 0.08). Advanced stage (stages III--IV) endometrial cancer at diagnosis was found in 5/33 (15%) Lumbee, 6/49 (12%) White, and 7/23 (30%) Black subjects (*p* = 0.15). The number of pelvic lymph nodes removed was similar between groups; there was a trend toward removal of more aortic lymph nodes in black subjects (median number in Lumbee 3; White 0; Black 5.5; *p* = 0.053). Rates of receipt of adjuvant chemotherapy or radiotherapy were not significantly different between cohorts.

The endometrial cancer recurrence rate was 10% for White, 12% for Lumbee, and 27% for Black subjects (*p* = 0.15). [Fig. 1](#f0005){ref-type="fig"} depicts Kaplan--Meier curves for DFS and OS. The 5-year DFS rates were 84% (68--100%) for Lumbee, 93% (86--100%) for White, and 58% (39--88%) for Black subjects (univariate *p* \< 0.001). In a multivariate Cox regression model to predict DFS while adjusting for age and BMI, race was a significant predictor (*p* = 0.01), with Black subjects having significantly shorter DFS than White or Lumbee subjects. The 5-year OS rates were 79% (62--100%) for Lumbee, 87% (78--97%) for White, and 65% (46--91%) for Black subjects (univariate *p* = 0.26). In a multivariate Cox regression model to predict OS while adjusting for age and BMI, race cohort was a borderline significant predictor (*p* = 0.054).

4. Discussion {#s0020}
=============

In this matched retrospective cohort study of women with endometrial cancer treated at two academic institutions in North Carolina, we examined the prevalence of biologically aggressive subtypes of endometrial cancer between Lumbee and non-Lumbee patients. We found no significant difference between cohorts in the prevalence of high-risk histologic subtypes, high-grade (FIGO grade \> 2), or advanced stage (stage III-IV) endometrial cancer. However there was a non-significant trend toward a difference in both high grade (*p* = 0.07) and high-risk histology (*p* = 0.08) when all 3 cohorts were compared, with Lumbees having a frequency of high-risk cancers between that of Whites and Blacks. Prior studies have demonstrated that Blacks have a higher rate of high-risk endometrial cancer subtypes and a poorer prognosis than Whites ([@bb0025], [@bb0030], [@bb0075], [@bb0040], [@bb0060], [@bb0065], [@bb0070], [@bb0090]). While we did not demonstrate poor cancer outcomes in the Lumbee cohort, the small size of our study likely limits our ability to assess this.

One compelling reason to investigate racial disparities in cancer characteristics and outcomes is the issue of access to care, which can differ significantly along racial lines in many cancers. For example, several recent studies have demonstrated differences in receipt of standard ovarian cancer treatments between Blacks and Whites, with a corresponding difference in survival outcomes ([@bb0085], [@bb0015]). Rather than a biologic or molecular cause, unequal application of treatment appeared to account for the differences in outcomes. The socioeconomic disparities and knowledge deficits about certain cancers seen in the general Native Americans population have also been observed in the Lumbee ([@bb0050]). The Lumbee Tribe of North Carolina is a unique group of Native Americans, alternately speculated to have descended from an admixture of seven Native American tribes in the South Eastern U.S., the Lost Colonists who settled in coastal North Carolina in the 1580s, and those of European and African American ancestry ([@bb0045], [@bb0055], [@bb0005]). It is currently unknown how certain genetic features of this culturally and ancestrally distinct population may influence cancer risks and mortality.

Limitations of this study include the lack of any official guidelines to identify Lumbee subjects. Our Lumbee identification criteria are not validated and may be overly restrictive; those who married outside of the Lumbee community and lost their traditional last names may not have been identified as Lumbee. Lumbee women may also have been misidentified or not identified racially in medical records. In fact, only 3 of the 36 Lumbee subjects in our study were specifically identified as Lumbee in their medical records. Historically, identification of Native Americans has been challenging and often inaccurate. For example, comparison of self-identified race from listed by the U.S. Census Bureau to state death records shows that 41% of Native Americans are recorded as non-native when someone else assigns their race ([@bb0035]). Other limitations include the small sample size, which limits the power to detect significant differences between cohorts. Finally, Lumbee subjects in our study sample may not be representative of all Lumbee, as women with the lowest risk cancers may have undergone hysterectomy closer to home than our institutions.

More work is needed to clarify the extent to which Lumbee heritage may contribute to endometrial cancer risk and outcomes. This population may benefit from increased education on endometrial cancer detection and risk reduction strategies, such as interventions to target obesity, a major risk factor. Better access to gynecologic oncology care through new and established referral pathways may also be a starting point in lowering barriers to care for the large Lumbee population in southeastern North Carolina.
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###### 

Pre-operative characteristics of 3 cohorts.

  Characteristics                       Lumbee         Whites        Blacks        *p*-Value
  ------------------------------------- -------------- ------------- ------------- -----------
  Age, median (IQR)                     62.2 (11.8)    64 (13.4)     58 (13.2)     0.09
  BMI, median (IQR)                     37.5 (12.1)    35.5 (12.8)   37.7 (13.0)   0.9
  Surgical year, median (IQR)           2006.5 (4.5)   2005 (14.0)   2008 (3.0)    0.1
  Smoker, number (%)                                                               
      Yes                               5 (15%)        7 (16%)       4 (18%)       0.9
      No                                29 (85%)       37 (84%)      18 (82%)      
      Not reported                      2              5             1             
  Cardiovascular diseases, number (%)                                              
      Yes                               5 (14%)        10 (21%)      4 (17%)       0.7
      No                                31 (86%)       37 (79%)      19 (83%)      
      Not reported                      0              2             0             
  Diabetic, number (%)                                                             
      Yes                               12 (33%)       12 (25%)      8 (35%)       0.6
      No                                24 (67%)       36 (75%)      15 (65%)      
      Not reported                      0              1             0             
  Hypertension, number (%)                                                         
      Yes                               25 (69%)       32 (67%)      14 (61%)      0.8
      No                                11 (31%)       16 (33%)      9 (39%)       
      Not reported                      0              1             0             
  Insurance status, number (%)                                                     
      Private insurance                 4 (11%)        15 (31%)      10 (43%)      0.03
      Medicare                          14 (39%)       15 (31%)      10 (43%)      
      Medicaid                          5 (14%)        2 (4%)        2 (9%)        
      No insurance                      3 (8%)         0 (0%)        1 (4%)        
      Unknown                           10 (28%)       17 (34%)      0 (0%)        

Note. IQR, interquartile range.

###### 

Operative results and outcomes of 3 cohorts.

  Operative results                                               Lumbee        Whites        Blacks        *p*-Value
  --------------------------------------------------------------- ------------- ------------- ------------- -----------
  FIGO grade, number (%)                                                                                    
      1                                                           12 (34%)      20 (41%)      6 (26%)       0.2
      2                                                           11 (32%)      17 (35%)      5 (22%)       
      3                                                           12 (34%)      12 (24%)      12 (52%)      
      Not reported                                                1             0             0             
  Histologic type, number (%)                                                                               
      Endometrioid                                                24 (68.6%)    34 (69.4%)    12 (52.2%)    
      Papillary serous                                            5 (14.3%)     3 (6.1%)      2 (8.7%)      
      Clear cell                                                  1 (2.8%)      1 (2.0%)      1 (4.4%)      
      Mucinous                                                    0 (0.0%)      1 (2.0%)      0 (0.0%)      
      Adenosquamous                                               1 (2.8%)      4 (8.2%)      0 (0.0%)      
      Mixed without clear cell or serous                          0 (0.0%)      1 (2.0%)      1 (4.4%)      
      Mixed with clear cell or serous                             3 (8.6%)      4 (8.2%)      5 (21.7%)     
      Carcinosarcoma                                              1 (2.8%)      1 (2.0%)      2 (8.7%)      
      Not reported                                                1             0             0             
  High-risk histologic type, number (%)                                                                     
      Yes                                                         10 (29%)      9 (18%)       10 (43%)      0.08
      No                                                          25 (71%)      40 (82%)      13 (57%)      
      Not reported                                                1             0             0             
  High-risk cancer[⁎](#tf0005){ref-type="table-fn"}, number (%)                                             
      Yes                                                         13 (37%)      15 (31%)      12 (52%)      0.2
      No                                                          22 (63%)      34 (69%)      11 (48%)      
      Not reported                                                1             0             0             
  FIGO stage, number (%)                                                                                    
      I--II                                                       28 (85%)      43 (88%)      16 (70%)      0.15
      III--IV                                                     5 (15%)       6 (12%)       7 (30%)       
      Not reported                                                3             0             0             
  \# pelvic nodes removed, median (IQR)                           11.5 (11.5)   13.0 (15.0)   15.0 (10.0)   0.3
  \# aortic nodes removed, median (IQR)                           3.0 (6.0)     0.0 (7.0)     5.5 (8.0)     0.053
  Adjuvant chemotherapy, number (%)                                                                         
      Yes                                                         6 (19%)       9 (18%)       9 (43%)       0.06
      No                                                          26 (81%)      40 (82%)      12 (57%)      
      Not reported                                                4             0             2             
  Adjuvant radiotherapy, number (%)                                                                         
      Yes                                                         13 (41%)      11 (22%)      8 (38%)       0.2
      No                                                          19 (59%)      38 (78%)      13 (62%)      
      Not reported                                                4             0             2             
  Recurrence, number (%)                                                                                    
      Yes                                                         4 (12%)       5 (10%)       6 (27%)       0.15
      No                                                          29 (88%)      44 (90%)      16 (73%)      
      Not reported                                                3             0             1             

Note. FIGO, International Federation of Gynecology and Obstetrics.

High risk cancer = papillary serous, grade 3, carcinosarcoma, or FIGO grade 3.

###### 

Operative results and outcomes of 2 cohorts (Lumbee vs. controls).

  Operative results                                               Lumbee        Non-Lumbee    *p*-Value
  --------------------------------------------------------------- ------------- ------------- -----------
  FIGO grade, number (%)                                                                      
      1                                                           12 (34%)      26 (36%)      1.0
      2                                                           11 (32%)      22 (31%)      
      3                                                           12 (34%)      24 (33%)      
      Not reported                                                1             0             
  Histologic type, number (%)                                                                 
      Endometrioid                                                24 (68.6%)    46 (63.9%)    
      Papillary serous                                            5 (14.3%)     5 (6.9%)      
      Clear cell                                                  1 (2.8%)      2 (2.8%)      
      Mucinous                                                    0 (0.0%)      1 (1.4)       
      Adenosquamous                                               1 (2.8%)      4 (5.6%)      
      Mixed without clear cell or serous                          0 (0.0%)      2 (2.8%)      
      Mixed with clear cell or serous                             3 (8.6%)      9 (12.5%)     
      Carcinosarcoma                                              1 (2.8%)      3 (4.2%)      
      Not reported                                                1             0             
  High-risk histologic types, number (%)                                                      
      Yes                                                         10 (29%)      19 (26%)      0.8
      No                                                          25 (71%)      53 (74%)      
      Not reported                                                1             0             
  High-risk cancer[⁎](#tf0010){ref-type="table-fn"}, number (%)                               
      Yes                                                         13 (37%)      27 (38%)      1.0
      No                                                          22 (63%)      45 (62%)      
      Not reported                                                1             0             
  FIGO stage, number (%)                                                                      
      I--II                                                       28 (85%)      59 (82%)      0.7
      III--IV                                                     5 (15%)       13 (18%)      
      Not reported                                                3             0             
  \# pelvic nodes removed, median (IQR)                           11.5 (11.5)   13.0 (15.0)   0.5
  \# aortic nodes removed, median (IQR)                           3.0 (6.0)     3.0 (8.0)     0.6
  Adjuvant chemotherapy, number (%)                                                           
      Yes                                                         6 (19%)       18 (26%)      0.4
      No                                                          26 (81%)      52 (74%)      
      Not reported                                                4             2             
  Adjuvant radiotherapy, number (%)                                                           
      Yes                                                         13 (41%)      19 (27%)      0.2
      No                                                          19 (59%)      51 (73%)      
      Not reported                                                4             2             
  Recurrence, number (%)                                                                      
      Yes                                                         4 (12%)       11 (15%)      0.6
      No                                                          29 (88%)      60 (85%)      
      Not reported                                                3             1             

Note. FIGO, International Federation of Gynecology and Obstetrics.

High risk cancer = papillary serous, grade 3, carcinosarcoma, or FIGO grade 3.
